SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiopharma Cred. Regulatory News (BPCR)

Share Price Information for Biopharma Cred. (BPCR)

Share Price is delayed by 15 minutes
Get Live Data
0.944    0.00 (0.00%)
Bid:
0.944
Ask:
0.946
Spread: 0.002 (0.212%)
Market Cap: $1.06b
BPCR Live PriceLast checked at - London Stock Exchange

Intraday Biopharma Cred. Share Chart

Dividend Declaration

8 Feb 2024 07:00

RNS Number : 3971C
BioPharma Credit PLC
08 February 2024
 

8 February 2024

 

BIOPHARMA CREDIT PLC 

("BIOPHARMA CREDIT" OR THE "COMPANY") 

DIVIDEND DECLARATION

2.96 CENT PER SHARE DISTRIBUTION INCLUDES 1.2 CENT SPECIAL DECLARATION

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to declare an interim dividend in respect of the financial period ending 31 December 2023 of $0.02957930 per ordinary share, payable on 15 March 2024 to ordinary shareholders on the register as at 16 February 2024. The ex-dividend date will be 15 February 2024. The Company has chosen to designate the entire amount of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company.

The $0.02957930 dividend comprises an ordinary dividend of $0.0175 and a special dividend of $0.01207930. The Company is currently paying and continues to target a 7 cent annual dividend per ordinary share. This will bring total dividends for 2023 to 10.21 cents including special dividends totalling 3.21 cents.

The default payment for dividends is in US dollars. However, shareholders can elect to have dividends paid in sterling (GBP) and the option to elect a sterling dividend payment for this dividend will be available to shareholders until 16 February 2024 (the "Election Date").

Further details together with a copy of the Dividend Currency Election Form, which should be sent to Link Group, 10th Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL when completed, will be available on the Group's website shortly at www.bpcruk.com/investor-materials. CREST shareholders must elect via CREST. Further details together with a copy of the Dividend Currency Election Form, which should be sent to Link Group, 10th Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL when completed, will be available on the Group's website shortly at www.bpcruk.com/investor-materials. CREST shareholders must elect via CREST.

Enquiries:

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0) 333 300 1950

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DIVTRMRTMTJMBJI
Date   Source Headline
1st Sep 20252:26 pmRNSTotal Voting Rights
26th Aug 20257:00 amRNSNotice of Half Year Results
22nd Aug 20254:00 pmRNSNet Asset Value(s) and Monthly Factsheet
21st Aug 202512:07 pmRNSTransaction in Own Shares - Correction
20th Aug 20256:16 pmRNSTransaction in Own Shares
12th Aug 20255:39 pmRNSDirector/PDMR Shareholding
31st Jul 20257:00 amRNSAppointment of New Director
21st Jul 20254:00 pmRNSNet Asset Value(s) and Monthly Factsheet
18th Jul 20254:23 pmRNSHolding(s) in Company
1st Jul 202512:02 pmRNSSTATEMENT RE BIOCRYST
24th Jun 20253:39 pmRNSHolding(s) in Company
20th Jun 20254:00 pmRNSNet Asset Value(s) and Monthly Factsheet
18th Jun 20257:00 amRNSDividend Declaration
10th Jun 202510:56 amRNSDirector Declaration
9th Jun 20254:37 pmRNSResult of AGM
22nd May 20254:00 pmRNSNet Asset Value(s) and Monthly Factsheet
22nd May 20257:00 amRNSUPDATE ON INVESTMENT PORTFOLIO
12th May 20253:36 pmRNSDirector/PDMR Shareholding
9th May 20254:34 pmRNSNotice of Annual General Meeting
6th May 20257:00 amRNSUPDATE ON INVESTMENTS
1st May 202512:36 pmRNSTotal Voting Rights
28th Apr 20254:00 pmRNSNet Asset Value(s) and Monthly Factsheet
11th Apr 20256:15 pmRNSTransaction in Own Shares
8th Apr 20256:15 pmRNSTransaction in Own Shares
7th Apr 20256:15 pmRNSTransaction in Own Shares
4th Apr 20256:15 pmRNSTransaction in Own Shares
3rd Apr 20256:15 pmRNSTransaction in Own Shares
2nd Apr 20256:15 pmRNSTransaction in Own Shares
2nd Apr 20255:21 pmRNSHolding(s) in Company
2nd Apr 20252:35 pmRNSBIOGEN SETTLEMENT
1st Apr 20256:15 pmRNSTransaction in Own Shares
1st Apr 202511:56 amRNSTotal Voting Rights
31st Mar 20256:15 pmRNSTransaction in Own Shares
27th Mar 20256:15 pmRNSTransaction in Own Shares
26th Mar 20256:15 pmRNSTransaction in Own Shares
25th Mar 20256:15 pmRNSTransaction in Own Shares
25th Mar 20257:01 amRNSDividend Declaration
25th Mar 20257:00 amRNSAnnual Financial Report
24th Mar 20256:15 pmRNSTransaction in Own Shares
21st Mar 20256:15 pmRNSTransaction in Own Shares
21st Mar 20255:19 pmRNSHolding(s) in Company
21st Mar 20254:00 pmRNSNet Asset Value(s) and Monthly Factsheet
21st Mar 20257:00 amRNSSTATEMENT RE OPTINOSE, INC.
20th Mar 20256:15 pmRNSTransaction in Own Shares
20th Mar 20257:00 amRNSAppointment of Joint Corporate Broker
19th Mar 20256:15 pmRNSTransaction in Own Shares
18th Mar 20256:15 pmRNSTransaction in Own Shares
18th Mar 202512:26 pmRNSHolding(s) in Company
17th Mar 20256:15 pmRNSTransaction in Own Shares
14th Mar 20256:15 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.